A phase II trial has demonstrated that insulin-like growth factor 1 receptor (IGF-1R) blockade in advanced neuroendocrine tumours has no efficacy, despite promising preclinical and phase I clinical trial evidence. These results highlight the challenge of interpreting response results from early phase I safety studies.
This is a preview of subscription content, log in via an institution to check access.
References
Strosberg, J. et al. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumours. Endocr. Relat. Cancer 20, 383–390 (2013).
Spiegel, A. M. & Libutti, S. K. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors. Nat. Rev. Clin. Oncol. 8, 258–259 (2011).
Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumours. N. Engl. J. Med. 364, 501–513 (2011).
Höpfner, M., Baradari, V., Huether, A., Schöfl, C. & Scherübl, H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr. Relat. Cancer 13, 135–149 (2006).
Vitale, L. et al. Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumors. Oncol. Rep. 15, 1249–1256 (2006).
Tolcher, A. W. et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800–5807 (2009).
Reidy-Lagunes, D. L. et al. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118, 4795–4800 (2012).
Shen, H. C. et al. Recapitulation of pancreatic neuroendocrine tumours in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res. 69, 1858–1866 (2009).
Quinn, T. J. et al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumours (PNETs) in a multiple endocrine neoplasia type 1(MEN1) conditional knockout mouse model. Surgery 152, 1068–1077 (2012).
Acknowledgements
The author would like to thank A. Spiegel (Albert Einstein College of Medicine) for his review of the manuscript and his helpful suggestions.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Libutti, S. Blockade of IGF-1R—not effective in neuroendocrine tumours. Nat Rev Endocrinol 9, 389–390 (2013). https://doi.org/10.1038/nrendo.2013.109
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.109
- Springer Nature Limited
This article is cited by
-
Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms
Nature Reviews Clinical Oncology (2016)